· Published by Health Canada · Official notice
The Health Products and Food Branch (HPFB) posts on the Health Canada web site safety alerts, public health advisories, press releases and other notices as a service to health professionals, consumers, and other interested parties. These advisories may be prepared with Directorates in the HPFB which includes pre-market and post-market areas as well as market authorization holders and other stakeholders. Although the HPFB grants market authorizations or licenses for therapeutic products, we do not endorse either the product or the company. Any questions regarding product information should be discussed with your health professional.
This is duplicated text of a letter from Bristol-Myers Squibb Canada.
Contact the company for a copy of any references, attachments or enclosures.
Help on accessing alternative formats, such as Portable Document Format (PDF), Microsoft Word and PowerPoint (PPT) files, can be obtained in the alternate format help section.
(PDF Version - 81 K)
Contact : MHPD
Notice about Health Canada advisories
12 May 2006
Subject: Updated safety information for TEQUIN*(gatifloxacin) and serious hypoglycemia and hyperglycemia
Bristol-Myers Squibb Canada, in collaboration with Health Canada, is informing you of new safety information regarding TEQUIN* (gatifloxacin), an antibiotic used to treat certain lung, sinus, or urinary tract infections, as well as certain sexually transmitted diseases.
Please be aware of the following important safety information that may be relevant to patients receiving TEQUIN. The Product Monograph for TEQUIN has been updated to reflect this new safety information. Bristol-Myers Squibb Canada has also issued a letter to health professionals advising them of this new safety information.
For more information about the revisions to the prescribing information for TEQUIN, patients should consult their healthcare professional. Patients should not discontinue their medication without consulting their physician first.
The full copy of the Product Monograph can be found at: www.bmscanada.ca
For media inquiries, please contact Mr. Marc Osborne, Bristol-Myers Squibb, (514) 333-2463.
The safety of patients is a priority for Bristol-Myers Squibb Canada Inc. Information about adverse drug reactions is gathered by both Bristol-Myers Squibb Canada and Health Canada, via its Canadian Adverse Drug Reaction Monitoring Program (CADRMP). Any suspected adverse drug reactions in patients receiving TEQUIN can be reported to:
Bristol-Myers Squibb Canada
2365 Côte-de-Liesse
Montréal, Québec
H4N 2M7
Tel : 866-463-6267
Any suspected adverse reaction can also be reported to:
Canadian Adverse Drug Reaction Monitoring Program (CADRMP)
Marketed Health Products Directorate
HEALTH CANADA
Address Locator: 0701C
OTTAWA, Ontario, K1A 0K9
Tel: (613) 957-0337 or Fax: (613) 957-0335
To report an Adverse Reaction, consumers and health professionals may call toll free:
Tel: 866 234-2345
Fax: 866 678-6789
cadrmp@hc-sc.gc.ca
The AR Reporting Form and the AR Guidelines can be found on the Health Canada web site or in The Canadian Compendium of Pharmaceuticals and Specialties.
For other inquiries related to this communication, please contact Health Canada at:
Marketed Health Products Directorate
Email: MHPD_DPSC@hc-sc.gc.ca
Tel.: (613) 954-6522
Fax.: (613) 952-7738
original signed by
Dan Chiche, MD
Vice-President, Scientific Affairs
* TM of Bristol-Myers Squibb Company used under licence by Bristol-Myers Squibb Canada